Nasal Insulin for AD. Paul Allen's crusade. AFZ Gen2 Nasal
Jan 25, 2016 14:54:04 GMT -5
afrezzamiracle, gwb, and 2 more like this
Post by lakers on Jan 25, 2016 14:54:04 GMT -5
www.psychiatryadvisor.com/alzheimers-disease-and-dementia/inhaled-insulin-improves-memory-dementia-treatment/article/430731/
August 05, 2015
Inhaled Insulin Eyed As a Dementia Treatment
the Psychiatry Advisor take:
Insulin delivered through the nasal cavity may improve memory in those suffering from dementia.
William Banks, MD a professor of internal medicine and geriatrics at the University of Washington School of Medicine and a physician at the Veteran’s Administration Puget Sound Medical Center, and colleagues made the discovery based on a mouse model.
In an object recognition test, which depends a mouse's natural curiosity for new things, old mice do not remember whether objects they are presented to play with are new or old. But, after a single dose of intranasal insulin, they can remember which objects they have seen before, the researchers reported in the Journal of Alzheimer’s Disease.
Although hundreds of trials are being conducted on Alzheimer’s, few are looking at insulin and how it affects cognition. Banks said there are probably 100 intranasal compounds that could be tested for treating Alzheimer’s.
“Before this study, there was very little evidence of how insulin gets into the brain and where it goes,” Banks said in a statement. “We showed that insulin goes to areas where we hoped it would go.”
Researchers at the UW Medicine, Veteran's Administration Puget Sound and Saint Louis University have made a promising discovery that insulin delivered high up in the nasal cavity goes to affected areas of brain with lasting results in improving memory.
The findings were published online July 30 in the Journal of Alzheimer's Disease.
Importantly, researchers also found that insulin does not go into the bloodstream when delivered intranasally, a major concern in the medical community because it would lower blood sugar levels. Additionally, repeated doses increased insulin's efficacy in aiding memory.
Paul Allen Takes On Alzheimer's With $7M In New Research Grants
JUL 14, 2015 @ 08:00 AM
www.forbes.com/sites/arleneweintraub/2015/07/14/paul-allen-takes-on-alzheimers-with-7m-in-new-research-grants/#28f02a675eb3
Paul Allen, philanthropist and co-founder of Microsoft MSFT +0.46%, has devoted many millions of dollars to unlocking the mysteries of the brain, and today he’s taking on a new challenge: Alzheimer’s disease. The Paul G. Allen Family Foundation, launched by the tech mogul and his sister, Jody Lynn, in 1988, has awarded $7 million in grants to five teams of researchers who are working on new ways of combating the degenerative brain disease.
The new grants were largely driven by Allen’s desire to overcome the hurdles plaguing the field of Alzheimer’s drug development, says Judy Lytle, manager of medical research for the organization’s life sciences portfolio. Clinical trials of experimental therapies to treat the disease have suffered a 99.6% failure rate. There have been a number of high-profile failures in recent years, including bapineuzumab from Pfizer PFE +0.00%, Johnson & Johnson JNJ +0.63%, and Elan ELN +% Pharmaceuticals in 2012.
Allen, who has often spoken about his mother’s battle against Alzheimer’s, has a policy of thinking outside the box when it comes to funding medical research, Lytle says. The most recent tranche of money, for example—which was awarded under an ongoing program called the Allen Distinguished Investigator (ADI) grants—went to teams that include both neurology experts and scientists who have other areas of expertise, such as immunology.
These projects could provide a deeper understanding of what’s going on in the brain before Alzheimer’s symptoms develop, Lytle says—and that could be essential to developing better treatments for patients. Although a handful of Alzheimer’s drugs have made it onto market, they merely lessen the symptoms and delay the progression of the disease. “If we understand that progression, maybe we can actually intervene at the appropriate time. But the first step is to understand what’s happening there.”
The Alzheimer’s program is the latest milestone in Allen’s plan to improve the world’s understanding of the brain. In May, the Allen Institute for Brain Science, which is backed by $500 million of his money, launched a cell types database containing information on 240 neurons.
Funding from philanthropists like Allen can be an important bridge for medical researchers who hope to ultimately win support from deep-pocketed investors like Big Pharma companies looking for fresh research to fill their pipelines. Federal funding for Alzheimer’s research currently stands at about $586 million a year, according to the Alzheimer’s Association, which recently celebrated a Senate Appropriations Committee proposal to boost that amount by 60%.
That’s good news, to be sure, but cross-disciplinary teams such as the ones Allen is supporting might have trouble accessing that money, Lytle says. Allen hopes to close that funding gap. “Paul is very interested in Alzheimer’s disease research—it hits close to home for him,” she says. “We’re in the process of putting together a 10-year plan for the topics we want to go after, and given that interest, I can see a role for neurodegenerative disease and Alzheimer’s specifically.”
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
clinicaltrials.gov/ct2/show/NCT01767909
ClinicalTrials.gov Identifier:
NCT01767909
Last updated: January 14, 2016
Sponsor:
University of Southern California
Collaborators:
National Institute on Aging (NIA)
Alzheimer's Therapeutic Research Institute
Wake Forest School of Medicine
Information provided by (Responsible Party):
Paul Aisen, University of Southern California
Purpose
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages. The emotional and financial burden of AD to patients, family members, and society is enormous, and is predicted to grow exponentially as the median population age increases. Current FDA-approved therapies are modestly effective at best. This study will examine a novel therapeutic approach using intranasal insulin (INI) that has shown promise in short-term clinical trials. If successful, information gained from the study has the potential to move INI forward rapidly as a therapy for AD. The study will also provide evidence for the mechanisms through which INI may produce benefits by examining key cerebral spinal fluid (CSF) biomarkers and hippocampal/entorhinal atrophy. These results will have considerable clinical and scientific significance, and provide therapeutically-relevant knowledge about insulin's effects on AD pathophysiology. Growing evidence has shown that insulin carries out multiple functions in the brain, and that insulin dysregulation may contribute to AD pathogenesis.
This study will examine the effects of intranasally-administered insulin on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid (CSF) biomarkers in amnestic mild cognitive impairment (aMCI) or mild AD. It is hypothesized that after 12 months of treatment with INI compared to placebo, subjects will improve performance on a global measure of cognition, on a memory composite and on daily function. In addition to the examination of CSF biomarkers and hippocampal and entorhinal atrophy, the study aims to examine whether baseline AD biomarker profile, gender, or Apolipoprotein epsilon 4 (APOE-ε4) allele carriage predict treatment response.
In this study, 240 people with aMCI or AD will be given either INI or placebo for 12 months, following an open-label period of 6 months where all participants will be given active drug. The study uses insulin as a therapeutic agent and intranasal administration focusing on nose to brain transport as a mode of delivery.
Technosphere nasal inhaler Gen2 was registered with FDA 4/20/2015
imgur.com/Ti7xJrj
Some infos here are gathered from madog365 on YMB.
www.psychiatryadvisor.com/alzheimers-disease-and-dementia/inhaled-insulin-improves-memory-dementia-treatment/article/430731/
August 05, 2015
Inhaled Insulin Eyed As a Dementia Treatment
the Psychiatry Advisor take:
Insulin delivered through the nasal cavity may improve memory in those suffering from dementia.
William Banks, MD a professor of internal medicine and geriatrics at the University of Washington School of Medicine and a physician at the Veteran’s Administration Puget Sound Medical Center, and colleagues made the discovery based on a mouse model.
In an object recognition test, which depends a mouse's natural curiosity for new things, old mice do not remember whether objects they are presented to play with are new or old. But, after a single dose of intranasal insulin, they can remember which objects they have seen before, the researchers reported in the Journal of Alzheimer’s Disease.
Although hundreds of trials are being conducted on Alzheimer’s, few are looking at insulin and how it affects cognition. Banks said there are probably 100 intranasal compounds that could be tested for treating Alzheimer’s.
“Before this study, there was very little evidence of how insulin gets into the brain and where it goes,” Banks said in a statement. “We showed that insulin goes to areas where we hoped it would go.”
Researchers at the UW Medicine, Veteran's Administration Puget Sound and Saint Louis University have made a promising discovery that insulin delivered high up in the nasal cavity goes to affected areas of brain with lasting results in improving memory.
The findings were published online July 30 in the Journal of Alzheimer's Disease.
Importantly, researchers also found that insulin does not go into the bloodstream when delivered intranasally, a major concern in the medical community because it would lower blood sugar levels. Additionally, repeated doses increased insulin's efficacy in aiding memory.
Paul Allen Takes On Alzheimer's With $7M In New Research Grants
JUL 14, 2015 @ 08:00 AM
www.forbes.com/sites/arleneweintraub/2015/07/14/paul-allen-takes-on-alzheimers-with-7m-in-new-research-grants/#28f02a675eb3
Paul Allen, philanthropist and co-founder of Microsoft MSFT +0.46%, has devoted many millions of dollars to unlocking the mysteries of the brain, and today he’s taking on a new challenge: Alzheimer’s disease. The Paul G. Allen Family Foundation, launched by the tech mogul and his sister, Jody Lynn, in 1988, has awarded $7 million in grants to five teams of researchers who are working on new ways of combating the degenerative brain disease.
The new grants were largely driven by Allen’s desire to overcome the hurdles plaguing the field of Alzheimer’s drug development, says Judy Lytle, manager of medical research for the organization’s life sciences portfolio. Clinical trials of experimental therapies to treat the disease have suffered a 99.6% failure rate. There have been a number of high-profile failures in recent years, including bapineuzumab from Pfizer PFE +0.00%, Johnson & Johnson JNJ +0.63%, and Elan ELN +% Pharmaceuticals in 2012.
Allen, who has often spoken about his mother’s battle against Alzheimer’s, has a policy of thinking outside the box when it comes to funding medical research, Lytle says. The most recent tranche of money, for example—which was awarded under an ongoing program called the Allen Distinguished Investigator (ADI) grants—went to teams that include both neurology experts and scientists who have other areas of expertise, such as immunology.
These projects could provide a deeper understanding of what’s going on in the brain before Alzheimer’s symptoms develop, Lytle says—and that could be essential to developing better treatments for patients. Although a handful of Alzheimer’s drugs have made it onto market, they merely lessen the symptoms and delay the progression of the disease. “If we understand that progression, maybe we can actually intervene at the appropriate time. But the first step is to understand what’s happening there.”
The Alzheimer’s program is the latest milestone in Allen’s plan to improve the world’s understanding of the brain. In May, the Allen Institute for Brain Science, which is backed by $500 million of his money, launched a cell types database containing information on 240 neurons.
Funding from philanthropists like Allen can be an important bridge for medical researchers who hope to ultimately win support from deep-pocketed investors like Big Pharma companies looking for fresh research to fill their pipelines. Federal funding for Alzheimer’s research currently stands at about $586 million a year, according to the Alzheimer’s Association, which recently celebrated a Senate Appropriations Committee proposal to boost that amount by 60%.
That’s good news, to be sure, but cross-disciplinary teams such as the ones Allen is supporting might have trouble accessing that money, Lytle says. Allen hopes to close that funding gap. “Paul is very interested in Alzheimer’s disease research—it hits close to home for him,” she says. “We’re in the process of putting together a 10-year plan for the topics we want to go after, and given that interest, I can see a role for neurodegenerative disease and Alzheimer’s specifically.”
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
clinicaltrials.gov/ct2/show/NCT01767909
ClinicalTrials.gov Identifier:
NCT01767909
Last updated: January 14, 2016
Sponsor:
University of Southern California
Collaborators:
National Institute on Aging (NIA)
Alzheimer's Therapeutic Research Institute
Wake Forest School of Medicine
Information provided by (Responsible Party):
Paul Aisen, University of Southern California
Purpose
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages. The emotional and financial burden of AD to patients, family members, and society is enormous, and is predicted to grow exponentially as the median population age increases. Current FDA-approved therapies are modestly effective at best. This study will examine a novel therapeutic approach using intranasal insulin (INI) that has shown promise in short-term clinical trials. If successful, information gained from the study has the potential to move INI forward rapidly as a therapy for AD. The study will also provide evidence for the mechanisms through which INI may produce benefits by examining key cerebral spinal fluid (CSF) biomarkers and hippocampal/entorhinal atrophy. These results will have considerable clinical and scientific significance, and provide therapeutically-relevant knowledge about insulin's effects on AD pathophysiology. Growing evidence has shown that insulin carries out multiple functions in the brain, and that insulin dysregulation may contribute to AD pathogenesis.
This study will examine the effects of intranasally-administered insulin on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid (CSF) biomarkers in amnestic mild cognitive impairment (aMCI) or mild AD. It is hypothesized that after 12 months of treatment with INI compared to placebo, subjects will improve performance on a global measure of cognition, on a memory composite and on daily function. In addition to the examination of CSF biomarkers and hippocampal and entorhinal atrophy, the study aims to examine whether baseline AD biomarker profile, gender, or Apolipoprotein epsilon 4 (APOE-ε4) allele carriage predict treatment response.
In this study, 240 people with aMCI or AD will be given either INI or placebo for 12 months, following an open-label period of 6 months where all participants will be given active drug. The study uses insulin as a therapeutic agent and intranasal administration focusing on nose to brain transport as a mode of delivery.
Technosphere nasal inhaler Gen2 was registered with FDA 4/20/2015
imgur.com/Ti7xJrj
Some infos here are gathered from madog365 on YMB.
